How much does a box of Tafasitamab cost?

Tafasitamab (Tafasitamab) is used in combination with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. The trade name approved for marketing in the United States is Monjuvi. In the EU, Tafaracetamumab is suitable for combination with lenalidomide, and subsequently combined with Tafaracetamumab alone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not suitable for autologous stem cell transplantation. The approved marketing name is Minjuvi.

Tafaracetam is available by prescription only and must be given by a health care professional experienced in cancer treatment. This medicine comes in powder form and can be made into a solution for intravenous infusion. Tafracetamumab treatment is given in 28-day cycles, and the dose is based on body weight, and doctors can adjust or stop treatment based on the patient's response to the infusion. Tafracetamumab can be administered in combination with lenalidomide for up to 12 cycles, after which tafracetamumab can be used alone. Continue treatment until disease progresses or side effects become unacceptable.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.